Cancer Biomarkers Market Insights: Impact of Biomarker-Based Clinical Trials on Market Growth
- sachi toshniwal
- 3 days ago
- 4 min read
The cancer biomarkers market involves the use of biological indicators—such as genes, proteins, and other molecules—to detect and monitor cancer. These biomarkers help in early diagnosis, predicting disease progression, and determining how well a patient may respond to treatment. As cancer cases continue to rise globally, the demand for accurate, non-invasive, and personalized diagnostic tools is growing. Technological advancements, especially in genomics and molecular biology, are driving innovation in this market. North America currently leads due to strong healthcare infrastructure and research funding, while the Asia-Pacific region is rapidly expanding. Despite its growth, challenges like high testing costs and regulatory hurdles remain.
According to Fortune Business Insights, the global cancer biomarkers market was valued at USD 38.14 billion in 2024 and is projected to grow from USD 42.87 billion in 2025 to USD 74.62 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.2% during the forecast period. In 2024, North America dominated the market with a 35.99% share.
Top Companies in the Cancer Biomarkers Market
Leading players in the cancer biomarkers industry include:
F. Hoffmann-La Roche Ltd.
Abbott
Thermo Fisher Scientific
Bio-Rad Laboratories, Inc.
CENTOGENE N.V.
Axon Medchem
Sino Biological Inc.
R&D System
BioVision Inc.
Myriad RBM
Other players
Key Industry Developments
March 2021: Roche announced that it received approval from the US Food and Drug Administration for the VENTANA ALK (D5F3) CDx Assay as a companion diagnostic. This assay is the only FDA-approved test for LORBRENA and aids in identifying patients with this cancer biomarker for more effective treatment.
Market Drivers and Restraints
Market Drivers:
Rising Prevalence of Cancer: The increasing global incidence of cancer is a significant factor propelling market growth. For instance, in 2018, an estimated 18.0 million people were diagnosed with cancer worldwide.
Advancements in Technology: Technological advancements in genomics and proteomics have facilitated the development of novel biomarkers, enhancing early detection and personalized treatment approaches.
Adoption of Personalized Medicine: The shift towards personalized medicine in cancer treatment is fueling the demand for cancer biomarkers, as they play a crucial role in diagnosis, prognosis, and therapy selection.
Research Collaborations: Collaborations between research institutions and key market players aim to develop biomarkers for disease diagnosis, further driving market growth.
Market Restraints:
Lack of Reimbursement Policies: The absence of reimbursement policies for biomarker testing in emerging and developed countries limits the demand for these biomarkers globally.
High Cost of Diagnosis: The high cost associated with cancer diagnosis and treatment in emerging countries restricts the number of patients undergoing biomarker testing.
Market Segments
By Cancer Type:
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Others
Breast cancer is expected to be the leading segment with respect to cancer type in this market during the forecast period, owing to its high prevalence and the increasing awareness about breast cancer diagnosis.
By Biomarker Type:
PSA
HER-2
EGFR
KRAS
Others
By End User:
Pharmaceutical & Biotechnology Companies
Diagnostics & Research Laboratories
Hospitals & Specialty Clinics
Other
Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/industry-reports/cancer-biomarkers-market-100630
Market Regional Insights
North America: North America dominated the global market in 2024, driven by the presence of key market players, advanced healthcare infrastructure, and significant investment in research and development.
Asia Pacific: The Asia Pacific region is expected to experience the highest growth during the forecast period, fueled by the increasing prevalence of cancer, government funding for product development, and growing awareness of cancer biomarkers among healthcare professionals and the public.
Future Market Scope
The cancer biomarkers market is poised for robust growth, with technological advancements and strategic collaborations playing a pivotal role. The integration of next-generation sequencing (NGS), liquid biopsy, and artificial intelligence (AI) into biomarker research is accelerating innovation in the field. Despite challenges such as high discovery costs and regulatory hurdles, the market holds immense potential, especially in emerging economies where healthcare infrastructure is expanding and demand for improved diagnostic tools is growing.
Conclusion
The global cancer biomarkers market is on a trajectory of significant growth, fueled by the rising prevalence of cancer, technological innovations, and the shift towards personalized medicine. As the demand for early and accurate cancer diagnosis escalates, the market is set to offer improved and accessible diagnostic solutions for patients worldwide.
Frequently Asked Questions (FAQ’s)
What is the market size of Cancer Biomarkers Market?
What factors are driving Cancer Biomarkers Market growth in North America?
Who are the major players in the Cancer Biomarkers Market?
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.
At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Comments